Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04547621
- Locations
- 🇨🇳
CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai, Shanghai, China
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04525014
- Locations
- 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-02-17
- Target Recruit Count
- 28
- Registration Number
- NCT04523688
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 33
- Registration Number
- NCT04514393
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Department of Hematology Nanfang Hospital, The Southern Medical University, Guandong, Guangdong, China
🇨🇳Guangdong 999 Brain Hospital, Guangzhou, Guangdong, China
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sapience Therapeutics
- Target Recruit Count
- 125
- Registration Number
- NCT04478279
- Locations
- 🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇬🇧University of Leeds, Leeds, United Kingdom
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT04477200
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 12
- Registration Number
- NCT04474353
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Philogen S.p.A.
- Target Recruit Count
- 226
- Registration Number
- NCT04443010
- Locations
- 🇨🇭
UniversitatSpital USZ, Zürich, Switzerland
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04400188
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 159
- Registration Number
- NCT04396860
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.